On November 11, 2022 BioInvent International AB (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, reported that a paper co-authored by researchers from BioInvent and Transgene is the recipient of this year’s Journal for ImmunoTherapy of Cancer (JITC) Best Oncolytic and Local Immunotherapy Paper Award (Press release, BioInvent, NOV 11, 2022, https://www.bioinvent.com/en/press/bioinvent-and-transgene-joint-paper-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy [SID1234624033]). The paper was highlighted at the annual Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) conference being held November 8-12, 2022, in Boston, MA, US.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The annual award, judged by a prestigious review committee of SITC (Free SITC Whitepaper) leadership and the JITC Editorial Board, recognizes one paper in the Oncolytic and Local Immunotherapy category for presenting outstanding research on the role of therapeutic agents designed to target tumor cells or the tumor microenvironment.
The winning paper, Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors, demonstrates in vivo proof of concept for Treg depleting immune checkpoint blocking vectorized αCTLA-4 as a highly effective and safe strategy to target CTLA-4.
Transgene and BioInvent are co-developing BT-001, an oncolytic virus developed using Transgene’s Invir.IO platform that is armed with an anti-CTLA-4 antibody to illicit a strong and effective anti-tumor response. The drug is currently being evaluated in a Phase 1/2a clinical trial as a single agent and in combination with the PD-1 checkpoint inhibitor KEYTRUDA (pembrolizumab) against solid tumors. Positive Phase 1 data announced in June 2022 confirmed the mechanism of action of BT-001 as a single agent and demonstrated first signs of anti-tumor activity.
The papers’ two co-first authors, Dr Monika Semmrich, Principal Scientist at BioInvent, and Dr Jean-Baptiste Marchand, Head of the Protein Science Lab at Transgene, will each receive a monetary prize. The award will be presented at the SITC (Free SITC Whitepaper) Meeting Awards Ceremony, taking place Friday, November 11 from 8:00 – 8:20 a.m. EST.
The full paper can be accessed here.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.